13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • SILLAJEN RCC

    Acronym: 

    JX594-REN026

    ACTRN/NCT /ethics: 

    NCT03294083

    Scientific title: 

    A study of recombinant vaccinia virus in combination with REGN2810 for renal cell carcinoma

    Summary of trial and patient characteristics

    Cancer Type Kidney
    Trial Type Treatment
    Phase Phase I Tumour Stream Kidney
    Age Range 18 years and older Cancer Stage Metastatic or Widespread
    Sex Both Anticipated Start Date 2018-06-07
    Molecular Target Anticipated End Date 2020-09-01
    Cancer Type Kidney
    Trial Type Treatment
    Phase Phase I
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Kidney
    Cancer Stage Metastatic or Widespread
    Anticipated Start Date 2018-06-07
    Anticipated End Date 2020-09-01

    Trial Summary

    This is a phase 1b open-label, multi-centre, dose escalation study of Pexa-Vec (Thyidine Kinase- deactivated vaccinia virus plus GM-CSF) in combination with REGN2810 (anti-PD-1) in patients with metastatic or unresectable renal cell carcinoma (RCC). The trial consists of a dose-escalation stage, where the maximum feasible dose of Pexa-Vec in combination with REGN2810 will be determined, followed by an expansion stage. During the expansion patients will receive REGN2810 alone or in combination with Pexa-Vec, which will be administered either through intravenous (IV) or intratumoral (IT) injection.

    Lay Summary

    A study of recombinant vaccinia virus in combination with REGN2810 for renal cell carcinoma

    Sponsor / Cooperative group

    SillaJen, Inc.

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Flinders Medical Centre Alex Scott-Hoy alex.scott-hoy@sa.gov.au 08 8204 4830 Recruiting